KRAS and pancreatic adenocarcinoma: Similar to our findings with immunotherapy biomarkers, we found these differences to be exemplified best in pancreatic adenocarcinomas, wherein B7-H3–high tumors displayed significant depletions for mutations in KRAS (56.8% vs. 85.5%, q < 0.0001), TP53 (47.9% vs. 76.5%, q < 0.0001), and RB1 (1.0% vs. 4.2%, q < 0.01).